Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies

The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Lotti Tajouri

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)

Abstract

As of June 2009, 361 genome-wide association studies (GWAS) had been referenced by the HuGE database. GWAS require DNA from many thousands of individuals, relying on suitable DNA collections. We recently performed a multiple sclerosis (MS) GWAS where a substantial component of the cases (24%) had DNA derived from saliva. Genotyping was done on the Illumina genotyping platform using the Infinium Hap370CNV DUO microarray. Additionally, we genotyped 10 individuals in duplicate using both salivaand blood-derived DNA. The performance of blood- versus saliva-derived DNA was compared using genotyping call rate, which reflects both the quantity and quality of genotyping per sample and the "GCScore," an Illumina genotyping quality score, which is a measure of DNA quality. We also compared genotype calls and GCScores for the 10 sample pairs. Call rates were assessed for each sample individually. For the GWAS samples, we compared data according to source of DNA and center of origin. We observed high concordance in genotyping quality and quantity between the paired samples and minimal loss of quality and quantity of DNA in the saliva samples in the large GWAS sample, with the blood samples showing greater variation between centers of origin. This large data set highlights the usefulness of saliva DNA for genotyping, especially in high-density single-nucleotide polymorphism microarray studies such as GWAS.

Original languageEnglish
Pages (from-to)794-798
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume19
Issue number3
DOIs
Publication statusPublished - 1 Mar 2010

Fingerprint

Saliva
Single Nucleotide Polymorphism
Genome-Wide Association Study
DNA
Multiple Sclerosis
Genotype
Databases

Cite this

The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) ; Tajouri, Lotti. / Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies. In: Cancer Epidemiology Biomarkers and Prevention. 2010 ; Vol. 19, No. 3. pp. 794-798.
@article{07d09d82b7bd41ef99f20445c5527e00,
title = "Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies",
abstract = "As of June 2009, 361 genome-wide association studies (GWAS) had been referenced by the HuGE database. GWAS require DNA from many thousands of individuals, relying on suitable DNA collections. We recently performed a multiple sclerosis (MS) GWAS where a substantial component of the cases (24{\%}) had DNA derived from saliva. Genotyping was done on the Illumina genotyping platform using the Infinium Hap370CNV DUO microarray. Additionally, we genotyped 10 individuals in duplicate using both salivaand blood-derived DNA. The performance of blood- versus saliva-derived DNA was compared using genotyping call rate, which reflects both the quantity and quality of genotyping per sample and the {"}GCScore,{"} an Illumina genotyping quality score, which is a measure of DNA quality. We also compared genotype calls and GCScores for the 10 sample pairs. Call rates were assessed for each sample individually. For the GWAS samples, we compared data according to source of DNA and center of origin. We observed high concordance in genotyping quality and quantity between the paired samples and minimal loss of quality and quantity of DNA in the saliva samples in the large GWAS sample, with the blood samples showing greater variation between centers of origin. This large data set highlights the usefulness of saliva DNA for genotyping, especially in high-density single-nucleotide polymorphism microarray studies such as GWAS.",
author = "{The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)} and Melanie Bahlo and Jim Stankovich and Patrick Danoy and Hickey, {Peter F.} and Taylor, {Bruce V.} and Browning, {Sharon R.} and Brown, {Matthew A.} and Rubio, {Justin P.} and Lotti Tajouri",
year = "2010",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-09-0812",
language = "English",
volume = "19",
pages = "794--798",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "3",

}

Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies. / The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) ; Tajouri, Lotti.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 19, No. 3, 01.03.2010, p. 794-798.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies

AU - The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)

AU - Bahlo, Melanie

AU - Stankovich, Jim

AU - Danoy, Patrick

AU - Hickey, Peter F.

AU - Taylor, Bruce V.

AU - Browning, Sharon R.

AU - Brown, Matthew A.

AU - Rubio, Justin P.

AU - Tajouri, Lotti

PY - 2010/3/1

Y1 - 2010/3/1

N2 - As of June 2009, 361 genome-wide association studies (GWAS) had been referenced by the HuGE database. GWAS require DNA from many thousands of individuals, relying on suitable DNA collections. We recently performed a multiple sclerosis (MS) GWAS where a substantial component of the cases (24%) had DNA derived from saliva. Genotyping was done on the Illumina genotyping platform using the Infinium Hap370CNV DUO microarray. Additionally, we genotyped 10 individuals in duplicate using both salivaand blood-derived DNA. The performance of blood- versus saliva-derived DNA was compared using genotyping call rate, which reflects both the quantity and quality of genotyping per sample and the "GCScore," an Illumina genotyping quality score, which is a measure of DNA quality. We also compared genotype calls and GCScores for the 10 sample pairs. Call rates were assessed for each sample individually. For the GWAS samples, we compared data according to source of DNA and center of origin. We observed high concordance in genotyping quality and quantity between the paired samples and minimal loss of quality and quantity of DNA in the saliva samples in the large GWAS sample, with the blood samples showing greater variation between centers of origin. This large data set highlights the usefulness of saliva DNA for genotyping, especially in high-density single-nucleotide polymorphism microarray studies such as GWAS.

AB - As of June 2009, 361 genome-wide association studies (GWAS) had been referenced by the HuGE database. GWAS require DNA from many thousands of individuals, relying on suitable DNA collections. We recently performed a multiple sclerosis (MS) GWAS where a substantial component of the cases (24%) had DNA derived from saliva. Genotyping was done on the Illumina genotyping platform using the Infinium Hap370CNV DUO microarray. Additionally, we genotyped 10 individuals in duplicate using both salivaand blood-derived DNA. The performance of blood- versus saliva-derived DNA was compared using genotyping call rate, which reflects both the quantity and quality of genotyping per sample and the "GCScore," an Illumina genotyping quality score, which is a measure of DNA quality. We also compared genotype calls and GCScores for the 10 sample pairs. Call rates were assessed for each sample individually. For the GWAS samples, we compared data according to source of DNA and center of origin. We observed high concordance in genotyping quality and quantity between the paired samples and minimal loss of quality and quantity of DNA in the saliva samples in the large GWAS sample, with the blood samples showing greater variation between centers of origin. This large data set highlights the usefulness of saliva DNA for genotyping, especially in high-density single-nucleotide polymorphism microarray studies such as GWAS.

UR - http://www.scopus.com/inward/record.url?scp=77949740924&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-0812

DO - 10.1158/1055-9965.EPI-09-0812

M3 - Article

VL - 19

SP - 794

EP - 798

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -